Fluvastatin attenuates doxorubicin-induced testicular toxicity in rats by reducing oxidative stress and regulating the blood–testis barrier via mTOR signaling pathway

Human and Experimental Toxicology - Tập 38 Số 12 - Trang 1329-1343 - 2019
Çevik Gürel1, Gökçe Ceren Kuşçu1, Aylin Buhur1, Melih Dağdeviren2, Fatih Oltulu1, Nefise Ülkü Karabay Yavaşoğlu2, Altuğ Yavaşoğlu1
1Department of Histology and Embryology, Faculty of Medicine, Ege University, İzmir, Turkey
2Department of Biology, Faculty of Science, Ege University, İzmir, Turkey

Tóm tắt

Doxorubicin (DOX) is an anthracycline derivative antibiotic that still frequently used in the treatment of solid tumors and hematological malignancies. The clinical use of DOX is largely restricted due to acute and chronic renal, cardiac, hematological, and testicular toxicities. Previous studies have indicated that oxidative stress, lipid peroxidation, and apoptosis in germ cells are the main factors in DOX-induced testicular toxicity, but the entire molecular mechanisms that responsible for DOX-induced testicular damage are not yet fully understood. Fluvastatin is a cholesterol-lowering agent that acts by inhibiting hydroxylmethyl glutaryl coenzyme A, the key enzyme for cholesterol biosynthesis. In addition to its cholesterol-lowering effect, fluvastatin showed an antioxidant effect by cleaning hydroxyl and superoxide radicals and this drug could have a protective effect by acting on the mammalian target of rapamycin (mTOR) signal pathway in testicular damage caused by obesity. This study aimed to investigate the possible protective and therapeutic effects of fluvastatin on the DOX-induced testicular toxicity model by histochemical, immunohistochemical, biochemical, and real-time polymerase chain reaction analyses. The present study indicates that fluvastatin may have a protective and therapeutic effect by removing reactive oxygen species and by regulating the mTOR, connexin 43, and matrix metalloproteinase 9 protein and messenger ribonucleic acid expressions, which play an important role in regulating the blood–testis barrier. On the other hand, the use of fluvastatin as a protective/prophylactic agent was found to be more effective than the use of this drug for treatment. In light of this information, fluvastatin may be a candidate agent that can be used to prevent testicular toxicity observed in men receiving DOX treatment.

Từ khóa


Tài liệu tham khảo

Dincer Y, 2014, Biomed Environ Sci, 27, 718

Valentovic MA, Advances in cancer research, 171

10.1039/C8FO00466H

10.1016/j.biopha.2017.03.002

10.1002/jbt.21937

10.4137/CMO.S32811

10.1186/s13287-018-0946-6

10.1016/j.bbrc.2018.03.044

10.2131/jts.26.51

10.1002/(SICI)1098-2280(1998)31:2<133::AID-EM5>3.0.CO;2-N

10.1007/s002040050617

10.1371/journal.pone.0182870

10.1089/ars.2015.6542

10.1093/humrep/des159

10.1186/1477-7827-10-79

10.1016/j.repbio.2018.03.002

10.1515/jbcpp-2018-0073

10.1080/15376516.2018.1512180

10.1530/REP-15-0129

10.1002/ptr.3633

10.1111/and.12173

10.1016/j.etp.2010.11.001

10.1016/j.yjmcc.2018.08.008

10.1016/j.bbadis.2017.07.030

10.3390/molecules22101589

10.4103/2319-4170.110365

10.1111/and.12811

10.1016/j.jbior.2016.12.001

10.1095/biolreprod.115.138016

10.1242/jcs.152231

10.1016/j.bbamem.2017.04.020

10.2165/00003495-200464120-00004

10.1046/j.1523-1755.2001.00724.x

10.1016/j.ebiom.2017.04.017

10.1507/endocrj.52.259

10.1111/j.1538-7836.2008.02913.x

10.1016/j.yexmp.2003.08.002

10.1007/s00380-013-0402-6

10.1159/000457881

Tannenbaum J, 2015, J Am Assoc Lab Anim Sci, 54, 120

10.1158/0008-5472.CAN-07-0376

10.1007/s13105-013-0240-0

10.11648/j.crj.20160406.13

10.1080/01926230290105721

Wang Y, Current Protocols in Toxicology, Unit16.6

10.1002/1099-1573(200009)14:6<432::AID-PTR622>3.0.CO;2-I

10.1111/j.1439-0272.2011.01269.x

Rao X, 2013, Biostat Bioinforma Biomath, 3, 71

10.1002/mus.20976

10.12717/DR.2016.20.3.237

Maitra SR, 2010, Int J Clin Exp Med, 3, 180

10.1158/0008-5472.CAN-04-1874

Johnsen SG, 1970, Hormones, 1, 2

10.1093/molehr/5.9.866

Mazur L, Frontiers in anti-cancer drug discovery, 110

10.1111/jphp.12539

10.1016/j.ijpharm.2007.01.031

10.20546/ijcmas.2017.607.330

10.1177/0192623312454337

Narayana K, 2000, Indian J Physiol Pharmacol, 44, 317

D’Souza UJA, 2003, Asian J Androl, 5, 217

10.1016/j.fct.2014.02.031

10.1146/annurev.physiol.63.1.193

10.1186/1477-7827-4-9

10.1016/j.etp.2014.12.002

10.1007/s00726-011-0904-4

10.1093/jn/135.4.757

10.1111/and.12635

10.1016/j.bcp.2007.06.031

10.1016/j.reprotox.2005.07.002

10.1016/j.acthis.2017.07.006

10.1111/j.1476-5381.2008.00042.x

10.1016/j.transproceed.2015.10.027

10.1016/S0278-6915(02)00111-4

Sudha M, 2011, Int J Pharma Bio Sci, 2, 214

10.1016/j.fertnstert.2005.11.035

10.1016/j.fct.2010.12.005

10.1016/j.cell.2017.02.004

10.3892/etm.2017.4881

10.1111/j.1432-2277.2006.00423.x

10.1016/j.rbmo.2015.11.007

Li N, 2016, Histol Histopathol, 31, 961

Thông tin
Thông tin xuất bản

Human and Experimental Toxicology

Tập 38 Số 12

1329-1343

Thông tin tác giả